Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff

Next Previous
Trial Profile

Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Spartalizumab (Primary) ; Tislelizumab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Anal cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Lung cancer; Male breast cancer; Malignant melanoma; Mesothelioma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Thyroid cancer; Uterine cancer; Uveal melanoma
  • Focus Therapeutic Use
  • Acronyms ACROPOLI

Most Recent Events

  • 04 Feb 2025 Status changed from recruiting to active, no longer recruiting.
  • 24 Oct 2023 Results assessing genes or gene expression signatures that can effectively indicate TLS abundance in the TME, irrespective of the cancer type in patients with advanced solid cancer participating in the molecular prescreening of this trial presented at the 48th European Society for Medical Oncology Congress
  • 24 Oct 2023 Results of exploratory analysis (n=1003) assessing the correlation between the presence of TILs and gene expression across multiple cancer types presented at the 48th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top